~~<i id='8D737C67FC'><strike id='8D737C67FC'><tt id='8D737C67FC'><pre id='8D737C67FC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：entertainment 2025-09-29 01:35:47 - browse：5

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Investment in vaccine development is lagging, report finds

focus

explore

hotspot

PatrickSison/APLow-doseaspirinledtoareductioninliverfatamongpatientswithmetabolic-associatedliverdis

WSS

Neuroscience’s long legacy of racism

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Orchard's therapy for neuron disease in children wins FDA approval

Orchard's therapy for neuron disease in children wins FDA approval

focus

fashion

focus

Heart attack and stroke risk calculators need revising

Humana’s losses in Medicare Advantage tank its stock

Medical records are filled with copy

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Duchenne breakthrough therapy leaves behind pioneering families

Baby aspirin cuts fat buildup in liver disease patients, in small study

Cancer drug shortages should be causing more outrage

Nurses recount patients attacks

Jerome Adams on the need for new antivirals for Covid

Virtual Event: March of the Biosimilars

focus

Readout Newsletter: Bluebird, CVS, Contineum

Nurses recount patients attacks

5 to watch: Tech startups trying to solve health care's staffing crisis

Future doctors should be trained to promote social change

Vertex non

Zyn nicotine pouches become unlikely player in latest culture war

focus

focus

explore

hotspot